English
Regional settings| Spread | 0.0084 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.8021 |
| Open | 0.7782 |
| 1-Year Change | -16.44% |
| Day's Range | 0.7728 - 0.9431 |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.
BRIEF: For the nine months ended 30 September 2021, Hookipa Pharma Inc revenues increased 1% to $14.6M. Net loss increased 72% to $54.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 60% to $58M (expense), Other income and expenses, net decrease from $1.6M (income) to $1.3M (expense).
